Nature communications · 2019
ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rashid Mamunur, van der Horst Michiel, Mentzel Thomas, Butera Francesca, Ferreira Ingrid, Pance Alena, Rütten Arno, Luzar Bostjan, Marusic Zlatko, de Saint Aubain Nicolas, Ko Jennifer S, Billings Steven D, Chen Sofia, Abi Daoud Marie, Hewinson James, Louzada Sandra, Harms Paul W, Cerretelli Guia, Robles-Espinoza Carla Daniela, Patel Rajiv M, van der Weyden Louise, Bakal Chris, Hornick Jason L, Arends Mark J, Brenn Thomas, Adams David J
Аннотация
Spiradenoma and cylindroma are distinctive skin adnexal tumors with sweat gland differentiation and potential for malignant transformation and aggressive behaviour. We present the genomic analysis of 75 samples from 57 representative patients including 15 cylindromas, 17 spiradenomas, 2 cylindroma-spiradenoma hybrid tumors, and 24 low- and high-grade spiradenocarcinoma cases, together with morphologically benign precursor regions of these cancers. We reveal somatic or germline alterations of the CYLD gene in 15/15 cylindromas and 5/17 spiradenomas, yet only 2/24 spiradenocarcinomas. Notably, we find a recurrent missense mutation in the kinase domain of the ALPK1 gene in spiradenomas and spiradenocarcinomas, which is mutually exclusive from mutation of CYLD and can activate the NF-κB pathway in reporter assays. In addition, we show that high-grade spiradenocarcinomas carry loss-of-function TP53 mutations, while cylindromas may have disruptive mutations in DNMT3A. Thus, we reveal the genomic landscape of adnexal tumors and therapeutic targets.
Предметные рубрики MeSH
AdultAgedAged, 80 and overCarcinoma, Adenoid CysticCohort StudiesDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNA Mutational AnalysisDeubiquitinating Enzyme CYLDFemaleHumansLoss of Function MutationMaleMiddle AgedMutation, MissenseProtein DomainsProtein KinasesSweat Gland NeoplasmsSweat GlandsTumor Suppressor Protein p53Exome Sequencing